AURX — Nuo Therapeutics Share Price
- $33.85m
- $33.27m
- $0.11m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 46.58 | ||
Price to Tang. Book | 46.58 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 69.73 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -380.26% | ||
Return on Equity | -179.39% | ||
Operating Margin | -716.64% |
Financial Summary
Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 1.37 | 0.15 | n/a | n/a | 0.11 | n/a | n/a | -31.06% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Nuo Therapeutics, Inc. is a regenerative therapies company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. Its flagship product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. The Company’s commercial offering consists of point of care technology for the safe and effective separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix (the Aurix System), which produces a platelet rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
Directors
- David Jorden CEO (53)
- Peter Clausen CSO (49)
- Shaun Martin OTH
- Lawrence Atinsky DRC
- Paul Mintz DRC
- Lyle Hohnke IND (72)
- Mark McLoughlin IND
- Eric Winzer IND (63)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- April 29th, 1998
- Public Since
- January 19th, 2017
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 42,316,516
- Address
- 8285 EL RIO, SUITE 150, HOUSTON, 77054
- Web
- https://www.nuot.com/
- Phone
- +1 8322369060
- Auditors
- Marcum LLP
Upcoming Events for AURX
Q1 2024 Nuo Therapeutics Inc Earnings Release
Q2 2024 Nuo Therapeutics Inc Earnings Release
Similar to AURX
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 19:16 UTC, shares in Nuo Therapeutics are trading at $0.80. This share price information is delayed by 15 minutes.
Shares in Nuo Therapeutics last closed at $0.80 and the price had moved by -72.88% over the past 365 days. In terms of relative price strength the Nuo Therapeutics share price has underperformed the S&P500 Index by -76.07% over the past year.
There is no consensus recommendation for this security.
Nuo Therapeutics does not currently pay a dividend.
Nuo Therapeutics does not currently pay a dividend.
Nuo Therapeutics does not currently pay a dividend.
To buy shares in Nuo Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.80, shares in Nuo Therapeutics had a market capitalisation of $33.85m.
Here are the trading details for Nuo Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AURX
Based on an overall assessment of its quality, value and momentum Nuo Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nuo Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +29.82%.
As of the last closing price of $0.80, shares in Nuo Therapeutics were trading -45.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nuo Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Nuo Therapeutics' management team is headed by:
- David Jorden - CEO
- Peter Clausen - CSO
- Shaun Martin - OTH
- Lawrence Atinsky - DRC
- Paul Mintz - DRC
- Lyle Hohnke - IND
- Mark McLoughlin - IND
- Eric Winzer - IND